The purpose of the study is to learn about the safety and effects of VERT-002 in treating these types of cancers. The study is divided into two parts. In the first part, researchers will determine the safest dose of VERT-002 and how well patients tolerate it. In the second part, they will further explore the drug’s effects and continue to monitor its safety. The study will help identify the best dose to use in future research.

Participants in the study will receive VERT-002 and will be closely monitored by healthcare professionals. The study will look at how the drug affects the cancer and any side effects that may occur. This research is important for developing new treatments for patients with advanced cancers that have limited options. The study is expected to continue for several years to gather comprehensive data on the drug’s effectiveness and safety.

The main aim is to see if the drug is safe and can shrink or stop the growth of these cancers. Children will receive the medicine in a series of visits where doctors check for side effects, adjust the dose if needed, and use simple scans to see whether the tumor is getting smaller. The study follows participants for several months to record any problems and to determine whether the cancer responds, using terms like “objective response rate” (the percentage of children whose tumors shrink) and “disease control” (tumors that stay the same size or get smaller).

The study has more than one part. In one part, EIK1005 is given by itself. In another part, EIK1005 is given with pembrolizumab. Participants may take the study tablet on a regular schedule and receive pembrolizumab through a vein during clinic visits. During the study, doctors watch for side effects and other health changes, and treatment may be adjusted as needed. The study also includes people with tumors that are MSI-H or dMMR, which are tumor features linked to problems in how cancer cells repair damage in their genetic material.

EIK1005 is also called a Werner helicase inhibitor. A helicase is a protein that helps cells handle and copy genetic material, and this medicine is designed to block that protein. The trial is planned to continue over several years while safety and dose information are collected.

During the study, participants receive telisotuzumab adizutecan as a solution for infusion, which means it is given slowly through a vein. The study team follows participants over time to watch for adverse events, which are unwanted health problems or side effects, and to see how the cancer changes while on treatment. The study looks at how long any cancer response lasts, how long the cancer stays under control, and overall survival.

This is a Phase 2 study, which means it is an early study in a larger group of people after initial testing has already been done. It focuses on a single treatment, so no other study medicine is listed. The study is planned to continue for several years.

The specific substance being tested is iomeprol, which is administered through an intravenous injection, meaning it is delivered directly into a vein. During the trial, participants will undergo imaging using both the standard dose and half the dose of the contrast. The study will evaluate how well the images show blood vessels and organs to ensure that using a smaller amount of the substance still provides clear and useful information for monitoring the disease.

The purpose of this study is to understand how pralsetinib affects the way the body processes certain other substances and hormones. Specifically, the study will look at how pralsetinib influences substances that are broken down by specific enzymes in the body called CYP3A4, CYP2C8, and CYP2C9, as well as hormones called estradiol and norethisterone acetate. This information is important because it helps doctors understand if pralsetinib might change how other medications or hormones work when taken at the same time.

During the study, patients will receive pralsetinib at a dose of up to 400 milligrams per day for a treatment period of up to 2 years. Blood samples will be collected at different times to measure the levels of the test substances and hormones in the body. The study will compare these measurements when the substances are given alone and when they are given together with pralsetinib. This will help researchers understand if pralsetinib changes how quickly or slowly the body processes these substances. The study is open-label, which means both patients and doctors will know what treatment is being given.

The purpose of this study is to test the safety of ALE.P03 and find the right dose to use, and then to see how well it works against these types of cancer. The study is divided into two main parts called Phase 1 and Phase 2. In Phase 1, different doses of the medication will be tested in small groups of patients to see which dose is safest and best tolerated. During this part, doctors will carefully watch for any side effects and check how the body handles the medication. In Phase 2, the chosen dose will be given to a larger group of patients to see how well the medication works at shrinking or controlling the cancer.

Patients joining this study must have already received standard treatments for their cancer, which may have included chemotherapy, certain antibodies that help the immune system fight cancer, and other medications depending on the type of cancer. The study requires a sample of tumor tissue to be tested in a laboratory to confirm that the CLDN1 protein is present at high enough levels. During the study, patients will have regular check-ups that include blood tests, physical examinations, heart monitoring using ECG, and scans to measure the size of the tumors. The doctors will track any side effects, measure how much medication is in the blood over time, and check whether the body develops an immune response to the medication. The study will continue until 2029.

The purpose of the study is to find out what doses of BMS-986517 are safe and how much people can tolerate in order to choose the best dose for future use, and to check if giving BMS-986517 at the chosen dose continues to be safe for people with specific cancers. The study will also monitor how often side effects occur, including serious side effects and those that might require stopping treatment. Additionally, the study will track whether tumors shrink and how long any responses last, as well as how the medication moves through and is processed by the body.

The study is divided into two parts. The first part focuses on testing different doses to determine which are safe and well tolerated. The second part uses the doses chosen from the first part to further evaluate safety in people with specific types of cancer. Participants will receive the medication through infusion and will be monitored for side effects during the first 21 days and throughout the treatment period, which can last up to 3 years from the first treatment, with additional monitoring for 30 days after the last treatment.

The study is done in two parts. In the first part, different doses of REGN10597 are tested alone and with cemiplimab to see how people tolerate the treatment. In the second part, more people receive the study treatment to learn more about its effect on the cancer. Participants are followed over time while the medicines are given and after treatment ends.

In the study, treatment is given over time and people are followed for several years. Some participants receive volrustomig by itself, while others receive it together with chemotherapy. During the study, health problems and side effects are watched closely, and treatment may be adjusted or stopped if needed. The study is designed to compare how the different treatment approaches work in these advanced cancers.

The purpose of this study is to determine how much of the drug can be safely given and to observe how the body processes it. During the first part of the study, different groups of participants will receive increasing amounts of KD033 to find the maximum dose that can be tolerated without causing severe side effects. This involves monitoring for dose limiting toxicities, which are harmful side effects that prevent further increases in the amount of medicine given. The study also looks at pharmacokinetics, which describes how the drug moves through the body, and pharmacodynamics, which refers to the drug’s effects on the body.

Following the initial dose adjustments, an expansion phase will occur to further observe the safety and early signs of how well the medication works. Throughout the process, researchers will monitor adverse events, which are any unexpected or unpleasant medical occurrences that happen during the treatment. The study also tracks the best overall response to see if the tumors shrink or stabilize in size after receiving the medication.

The purpose of this study is to find out the best dose of GSK5764227 that can be given safely with these standard treatments and to see how well it works in treating these cancers. The study will also check what side effects occur and how the body processes the medicine. During the study, patients will receive GSK5764227 through a vein along with their standard treatment medicines. Some medicines will be given through a vein while others are taken by mouth as tablets. Doctors will regularly check patients through physical exams, blood tests, and scans to see how the cancer is responding to treatment and to monitor for any side effects. Blood samples will also be collected to measure the levels of the study medicine in the body and to look for any immune responses to it.

Throughout the study, doctors will measure several things to understand how well the treatment works. They will look at how many patients have their tumors shrink or disappear, how long the cancer stays under control, and how long patients live without their cancer getting worse. For prostate cancer patients, doctors will also measure levels of a substance called PSA in the blood, which is a marker that helps track prostate cancer. The study will also carefully track any side effects or health changes that occur during treatment to understand the safety of this combination of medicines.

In the first part of the trial, small groups of participants will receive increasing amounts of the drug given by an intravenous infusion (a medicine delivered directly into a vein) to determine how the body tolerates it and to find the dose that seems most promising. Once a recommended dose is set, the second part continues with more participants receiving that dose, while doctors watch for side effects and check how the tumors respond. Tumor changes are measured using a standard method called RECIST v1.1, which compares scans taken before and after treatment to see if the cancer gets smaller, stays the same, or grows.

Throughout the study, participants will have regular medical visits, blood tests, and imaging scans to monitor safety and any signs that the tumor is responding. Researchers will record any adverse events, track how long any tumor shrinkage lasts, and note how long participants remain free from disease progression. The overall goal is to gather information that could lead to larger studies and eventually new treatment options for people with advanced solid tumors.

The main goal is to determine whether the medicine can be given safely, to identify the appropriate dose, and to see early signs that it may shrink or control the tumors.

Participants will take the capsule by mouth on a regular schedule. In the first part of the trial, the dose is adjusted to find the level that is tolerated without serious side effects. In the second part, patients with colorectal cancer or endometrial cancer receive the selected dose and are monitored with routine visits, blood tests, and imaging scans to check for tumor response and any side effects.

Participants in the study may receive the experimental medication as a single treatment or alongside other anti-cancer agents. During the trial, researchers will monitor how the body processes the medicine and how the drug moves through the bloodstream. The investigation aims to determine the most effective dose and schedule for the treatment while watching for any side effects that may occur.

During the course of the study, participants may receive the treatments through an intravenous infusion, which means the medicine is delivered directly into a vein. The study is divided into two parts to first determine the safest way to give the medication and then to see how well the combination of drugs can shrink or control the tumors.

The purpose of this study is to see how well valemetostat works in shrinking or controlling these specific types of tumors and to check how safe it is for patients. The study will measure how many patients respond to the treatment, which means their tumors get smaller or disappear. The study will also look at how long the response lasts, how long patients live without their cancer getting worse, overall survival, and any side effects that occur. Patients will be divided into different groups based on which gene change their tumor has or what type of cancer they have, such as clear cell kidney cancer, mesothelioma (a cancer that affects the lining of organs), or other types of solid tumors with these specific gene changes.

During the study, patients will take valemetostat tablets for up to 24 weeks, and possibly longer depending on how well the treatment works. Patients will have regular visits where doctors will check the size of their tumors using imaging scans and monitor their health through blood tests and physical examinations. The study will also collect tumor tissue samples to confirm the presence of the gene changes and to study how the treatment affects the cancer cells. Patients will be asked to complete questionnaires about their quality of life and any symptoms they experience. Some patients may also be asked to wear a device that tracks physical activity and other health measurements, and to participate in interviews about their experience with the treatment.

The study is divided into two parts. In the first part, called Phase 1, the researchers will test different doses of WEF-001 to find out which dose is safe and appropriate for further testing. They will closely watch for any side effects and measure how the medicine moves through the body. In the second part, called Phase 2a, the study will focus on one specific type of cancer from among pancreatic cancer, colorectal cancer, or non-small cell lung cancer, and will test whether WEF-001 can help shrink tumours at the dose chosen from Phase 1.

People taking part in the study must have already tried at least one standard treatment for their cancer that did not work or stopped working. During the study, participants will receive WEF-001 and will have regular check-ups that include blood tests, scans to measure tumours, and monitoring for any side effects. The study will continue to follow participants to see how long the treatment works and how it affects their overall health. Some participants may also have tissue samples taken from their tumour to help researchers learn more about how WEF-001 works.

The purpose of the study is to check the safety of CRN09682 and to see how well it works in treating these types of cancers. The study has two main parts. In the first part, different amounts of the medication will be tested in small groups of people to find out which dose is safe and appropriate to use. In the second part, a larger group of people will receive the dose that was selected from the first part to learn more about its safety and effectiveness. During the study, doctors will monitor for any side effects and will check how the cancer responds to the treatment.

People joining this study will have regular medical visits where they will receive the study medication and undergo tests to check their health and see how their cancer is responding. The study will look at whether the tumors get smaller, stay the same size, or grow, and will measure how long any positive effects last. Blood samples will be taken to measure the levels of CRN09682 and MMAE in the body. MMAE is a substance that is part of how the medication works against cancer cells. The study will also use special imaging tests that can detect somatostatin receptors to see changes in the tumors over time.

The purpose of the study is to find out what dose of GSK4524101 can be given safely, either alone or together with niraparib, and to see if the combination of these two drugs can help slow down or stop the growth of cancer. The study is divided into two parts. In the first part, small groups of people will receive increasing doses of GSK4524101 alone or combined with niraparib to find the highest dose that can be given without causing serious side effects. This part will also include a group to test whether taking GSK4524101 with food affects how the body processes the medication. In the second part, a larger group of people with the specific type of breast cancer described above will receive the combination of GSK4524101 and niraparib at a dose determined to be safe from the first part, to learn more about whether this combination can help shrink tumors.

Throughout the study, participants will have regular check-ups where doctors will monitor for any side effects and take blood samples to measure the amount of medication in the body. The study will also assess how well the treatment works by looking at whether tumors shrink or stop growing, and how long any positive effects last. Participants in the first part will help determine the safest dose to use, while those in the second part will help show whether the combination treatment can provide benefit for people with this specific type of breast cancer who have not previously received a PARP inhibitor.

The medication being studied, RVU120, comes in the form of capsules that are taken by mouth. The treatment can be given either alone or combined with other medications, depending on how the patient was treated in their previous study. The maximum daily amount that can be given is 150 milligrams, and treatment may continue for up to 5 months.

During the study, doctors will monitor how well patients tolerate the medication by checking for any side effects or health problems that may occur. The study will track how long patients can continue taking the medication before they need to stop treatment for any reason. This helps researchers understand both the long-term safety and effectiveness of RVU120 in treating these types of cancer.

The medications are available in different forms to make them suitable for children – including tablets that can be dissolved in water, hard capsules, and oral solution powder. The study will monitor how these treatments affect the participants’ growth, development, and overall health over time. The medications are taken by mouth daily, and patients will continue receiving the same treatment they were getting in their previous studies.

Throughout the study, doctors will track any health changes and measure important aspects of development such as height, weight, bone growth, and heart function. The study will continue following patients for several years to understand how the treatments affect young patients in the long term.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The purpose of this research is to understand how safe the medication is and how well patients tolerate it, while also examining its effectiveness against these types of cancer. The study is divided into two parts. In the first part, researchers will determine the safe dose of the medication. In the second part, they will focus on how well the treatment works in fighting the cancer.

During the study, participants will receive WEF-001 as a single treatment. The medication will be given in the form of a powder that is mixed with liquid and then administered through a vein. Participants will be monitored regularly to check their response to the treatment and any side effects that may occur. The study will include patients whose cancer has continued to grow after trying at least one standard treatment.

The research aims to understand how safe and effective DCC-3084 is in treating different types of cancer, including non-small cell lung cancer, melanoma (skin cancer), pancreatic cancer, and prostate cancer. The study is divided into two parts – the first part finds the right dose of the medicine, while the second part tests how well the chosen dose works in treating cancer.

During the study, participants will receive DCC-3084 and undergo regular medical check-ups to monitor their health and how well the treatment is working. The medicine targets specific changes in cancer cells, particularly mutations in genes called KRAS, BRAF, HRAS, NRAS, CRAF, and NF1, which are known to be involved in cancer growth.

During the study, participants will receive BMS-986482 either as tablets taken by mouth, or in combination with other medications that are given through injections under the skin or through an intravenous infusion (a slow drip into a vein). The study includes different groups of patients with various types of advanced cancers, such as non-small cell lung cancer, melanoma, colorectal cancer, breast cancer, and other solid tumors.

The researchers will monitor participants’ health throughout the study to check for any side effects from the treatment. They will also look at how well the medications work together and measure if the tumors respond to the treatment. The study includes regular medical check-ups and imaging tests to track the progress of the disease.

The study is designed in multiple parts. Part 1 focuses on finding the maximum tolerated dose or maximum administered dose and the recommended dose for further evaluation. Part 2 continues to assess safety and tolerability at the established dose. Participants must have specific genetic mutations in genes such as BRCA1, BRCA2, PALB2, RAD51B, RAD51C, or RAD51D. These are genes involved in DNA repair, and mutations in these genes may make cancer cells more susceptible to certain treatments.

The trial is “open-label,” which means both doctors and patients know which treatment is being given. Patients will receive the medication orally (by mouth) and will be monitored for side effects and response to treatment. Some patients with brain metastases (cancer that has spread to the brain) may also be eligible to participate under specific conditions.

The medication being studied, GSK4418959, works by inhibiting a protein called DNA Helicase Werner, which some cancer cells rely on to repair their DNA. In some parts of the study, GSK4418959 will be tested in combination with a type of immunotherapy called a PD-1 inhibitor, which helps the immune system recognize and attack cancer cells.

The study is divided into three parts. The first part will determine the appropriate dose of GSK4418959 when used alone. The second part will evaluate how well the medication works against colorectal and endometrial cancers. The third part will test GSK4418959 in combination with immunotherapy to determine the best dose for this combination approach.

The purpose of this study is to assess the safety and effectiveness of the combination of Valemetostat Tosylate and DXd ADCs in treating these cancers. The study is conducted in two phases. The first phase is designed to find the safest dose of the medications when used together, while the second phase aims to evaluate how well the treatment works. Participants will receive the medications and be monitored for any side effects and improvements in their condition. The study will help determine the best dose and gather information on how the treatment affects the cancer.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the progress of their cancer. These tests may include imaging scans like computed tomography (CT) or magnetic resonance imaging (MRI) to assess the size and spread of the tumors. The study is expected to continue for several years, providing valuable data on the potential benefits and risks of these treatments for patients with these specific types of cancer.

The purpose of the study is to test the safety and effectiveness of OncoGreen in helping surgeons better visualize tumor tissues and their edges during operations. The study will be conducted in two phases. In the first phase, the focus will be on ensuring that OncoGreen is safe and determining the best dose to use. In the second phase, the study will look at how well OncoGreen helps in seeing the tumors during surgery using a technique called fluorescence imaging, which makes the tumors glow under a special light.

Participants in the study will receive OncoGreen through an intravenous infusion, which means it will be delivered directly into their bloodstream. The study will monitor how well the tumors can be seen during surgery and check for any side effects. The goal is to improve the ability to see and remove tumors completely, which could lead to better outcomes for patients undergoing surgery for these types of cancers.

The study involves administering Niraparib, which is taken as a tablet by mouth, and Dostarlimab, which is given as an infusion into a vein. Participants will receive these treatments over a period of up to 24 months. Throughout the study, the response of the tumors to the treatment will be monitored to assess the effectiveness and safety of the drug combination.

Participants will be regularly checked to see how their cancer is responding to the treatment and to monitor any side effects. The study aims to provide valuable information on whether this combination of medications can help improve outcomes for patients with these specific types of cancer.

Participants in the study will receive a special injection called Fludeoxyglucose (18F)-Curium, which is a solution used to help visualize certain processes in the body. This solution is given through an intravenous infusion, meaning it is delivered directly into the bloodstream. The purpose of the study is to collect data on how often these immune-related side effects occur, how they affect patients with and without existing joint or muscle conditions, and how patients respond to treatment.

The study will follow participants over time to observe the development of these side effects and gather information on their health and treatment responses. This information will help doctors better understand and manage these side effects in the future, improving care for patients undergoing cancer treatment with immune checkpoint inhibitors.

Participants in the study will receive MK-3120 to see how their bodies respond to the treatment. The study will monitor the number of participants who experience any side effects and those who may need to stop the treatment due to these effects. Additionally, the study will look at how well the treatment works by measuring the response rate, how long the response lasts, and the overall survival of participants. The study will also track how the drug moves through the body, including its concentration levels over time.

This study is open-label, meaning both the researchers and participants know what treatment is being given. It is designed to help understand the potential benefits and risks of MK-3120 for people with advanced solid tumors who have already tried other treatments without success. The study is expected to continue until early 2028, with recruitment starting in 2025.

The study is divided into two parts. In the first part, the focus is on finding a safe and tolerable dose of IPN01195 for participants. This involves gradually increasing the dose to see how the body reacts and to identify the most suitable dose range. In the second part, the study aims to confirm the best dose of IPN01195 for specific types of tumors. Participants will take the medicine in the form of a coated tablet, which is taken orally, meaning it is swallowed.

Throughout the study, researchers will monitor participants for any side effects and measure how the medicine is processed in the body. They will also assess the medicine’s ability to shrink or control the tumors. The study will help determine if IPN01195 can be a potential treatment option for people with advanced solid tumors. The trial is expected to continue for several years to gather comprehensive data on the medicine’s effects.

The purpose of the study is to evaluate the safety and effectiveness of ALE.P02 when used alone in adult patients with these specific types of tumors. The study will be conducted in two phases. In the first phase, the focus will be on determining the safest dose of the treatment. In the second phase, the study will assess how well the treatment works against the cancer. Participants will receive the treatment through an intravenous infusion, which means the medicine will be given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study aims to gather information on how the treatment affects the cancer and the overall health of the participants. This information will help researchers understand the potential benefits and risks of using ALE.P02 for treating these types of cancers.

The purpose of the study is to evaluate how well this combination treatment works in controlling these cancers. Participants will receive the immune checkpoint inhibitors through an intravenous infusion, which means the medication is given directly into a vein. The study will also involve carbon ion radiotherapy, a type of radiation treatment that uses charged particles to target cancer cells. This approach is being tested to see if it can improve the effectiveness of the immune therapy in a palliative setting, which is aimed at relieving symptoms and improving quality of life.

Throughout the study, participants will have regular visits to monitor their health and the response of their cancer to the treatment. This will include imaging tests like CT or MRI scans to measure the size of the tumors and assess any changes. The study will last for a period of time, during which the safety and potential side effects of the treatment will also be closely observed. The goal is to gather information that could lead to better treatment options for these types of cancer in the future.

The purpose of this study is to find the best dose of Fianlimab and the best time to perform a special type of imaging called PET scan to see how the treatment is working. A PET scan is a test that helps doctors see how organs and tissues inside the body are functioning. The study will also look at how safe Fianlimab is for patients. Participants will receive the treatment and undergo PET scans before and during their treatment with Cemiplimab, with or without chemotherapy. The study will help researchers understand how the treatment affects the body and how well it works against the cancer.

Throughout the study, patients will be monitored closely to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information that could lead to better treatment options for people with advanced solid cancers. By understanding how these medications work together, researchers hope to improve outcomes for patients facing these challenging diseases.

Participants in the study will receive the treatment and be monitored for any side effects or changes in their condition. The study will also look at how the body processes the drug, including how long it stays in the body and how it is eliminated. This information will help researchers understand the drug’s effects and how it might benefit patients with advanced solid tumors.

The trial will continue until 2027, with the aim of gathering enough data to evaluate the treatment’s effectiveness and safety. Participants will be closely observed throughout the study to ensure their well-being and to collect valuable information that could lead to new treatment options for those with advanced solid tumors.

The purpose of this study is to evaluate the safety and effectiveness of ANV600, both by itself and when used with pembrolizumab, in treating advanced solid tumors. Participants in the study will receive these treatments through an infusion, which means the medication is given directly into the bloodstream. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of ANV600 that can be safely given to patients. In the second phase, they will assess how well the treatment works in reducing the size of tumors.

Throughout the study, participants will be closely monitored for any side effects or reactions to the treatment. The study aims to find out how long the treatment can keep the cancer from getting worse and how long patients can live after receiving the treatment. This research is important for developing new ways to treat advanced cancers and improve the quality of life for patients with these conditions.

The study involves taking RVU120 in the form of capsules. Participants will receive this treatment over a period of time, with the goal of determining the best dose and observing any effects on the tumors. The trial is divided into two parts: the first part focuses on finding the right dose, while the second part looks at the treatment’s effectiveness in specific types of tumors.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how the treatment affects their condition. The trial will help researchers learn more about RVU120 and its potential as a treatment option for people with advanced solid tumors who have not had success with standard therapies.